Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: An insight into the Women's Health Initiative Study

Cancer Research

Volumn 74, Issue 23, 2014, Pages 7060-7068

  Sweeney, Elizabeth E ^a   Fan, Ping ^a   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ESTRADIOL; GLUCOCORTICOID RECEPTOR; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR; GLUCOCORTICOID; NORETHISTERONE; PROGESTERONE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; LONG TERM CARE; POSTMENOPAUSE; SGK1 GENE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; RISK; WOMEN'S HEALTH;

APOPTOSIS; BREAST NEOPLASMS; DEXAMETHASONE; ESTROGENS; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; MCF-7 CELLS; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHINDRONE; POSTMENOPAUSE; PROGESTERONE CONGENERS; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; RISK; WOMEN'S HEALTH;

EID: 84917706481     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1784     Document Type: Article

References (35)

1. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
2. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
3. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5.
4. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996;Suppl D:9-14.
5. Haarbo J, Hansen BF, Christiansen C. Hormone replacement therapy prevents coronary artery disease in ovariectomized cholesterol-fed rabbits. APMIS 1991;99:721-7.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
8. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 2009;11:206-18.
9. Maximov PY, Lewis-Wambi JS, Jordan VC. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther 2009;4:88-103.
10. Jordan VC. The 38th David A. Karnofsky Lecture: the paradoxical actions of estrogen in breast cancer-Survival or death? J Clin Oncol 2008;26:3078-82.
11. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs. high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774-80.
12. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A 2011;108:18879-86.
13. Fan P, Griffith OL, Agboke FA, Anur P, Zou X, McDaniel RE, et al. c-Src modulates estrogen-induced stress and apoptosis in estrogendeprived breast cancer cells. Cancer Res 2013;73:4510-20.
14. Fan P, Agboke FA, McDaniel RE, Sweeney EE, Zou X, Creswell K, et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer 2014;50:457-68.
15. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal hysterectomy: extended follow-up of the Women's Health Initiative Randomised Trial. Lancet Oncol 2012;13:476-86.
16. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-30.
17. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP. Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 2005;242:23-32.
18. Fan P, McDaniel RM, Kim HR, Clagett D, Haddad B, Jordan VC. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer 2012;48:3488-98.
19. Gascoyne DM, Kypta RM, Vivanco MD. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem 2003;278:18022-9.
20. Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A. Glucocorticoid receptor and breast cancer. Breast Cancer Res Treat 2011;130:1-10.
21. Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013;19:6163-72.
22. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-46.
23. Catherino WH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-52.
24. Tuelings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 1980;40:2557-61.
25. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011;76:636-52.
26. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49-63.
27. Obiorah IE, Fan P, Jordan VC. Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state. Cancer Prev Res 2014;7:939-49.
28. Uht RM, Anderson CM, Webb P, Kushner PJ. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 1997;138:2900-8.
29. Miranda TB, Voss TC, Sung MH, Baek S, John S, Hawkins M, et al. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res 2013;73:5130-9.
30. Karmakar S, Jin Y, Nagaich AK. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) a and activator protein 1 (AP1) in dexamethasone-mediated interference of ERa activity. J Biol Chem 2013;288:24020-34.
31. Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long term adjuvant tamoxifen therapy. J Natl Cancer Inst 2014;106:pii dju296.
32. Jordan VC. Timing is key to avoid the bad and enhance the good of soy supplements. JNCI. In press.
33. Obiorah I, Jordan VC. Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause 2013;20:372-82.
34. Beral V, Reeves G, Bull D, Green J Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
35. Jordan VC. A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause 2014;21:1160-4.